ANI Pharmaceuticals Posts Record Q2 Revenue of $266M, a 26% YoY Jump, and Reaffirms Full-Year Guidance
ANIP sits 16% above its 52-week low of $64.99 on elevated volume (2.1× avg).
Summary
Record Q2 2026 revenue of $266 million, a 25.9% year-over-year increase, was accompanied by a reaffirmation of full-year guidance. Cortrophin Gel led the charge with a 43.5% revenue jump.
Key Events · Earnings and Guidance · ANIP
-
Record Q2 Revenue
Revenue reached $266 million, up 25.9% from $211.4 million in Q2 2025, driven by Cortrophin Gel and generics growth.
-
Cortrophin Gel Surge
Cortrophin Gel revenue jumped 43.5% to $117.1 million, reflecting market share gains and overall ACTH market growth.
-
Profitability Doubles
Net income available to common shareholders rose to $24.7 million, or $1.05 per diluted share, compared to $8.1 million, or $0.36 per share, a year ago.
-
Full-Year Guidance Reaffirmed
Management reiterated its 2026 outlook, indicating confidence in continued operational momentum.
Analysis · ANIP · Life Sciences
A standout second quarter saw revenue climb 25.9% to $266 million, fueled by a 43.5% surge in Cortrophin Gel sales. Net income more than doubled to $24.7 million, underscoring the operating leverage in the business. The company reaffirmed its full-year 2026 guidance, signaling confidence in the trajectory ahead. The balance sheet also strengthened, with cash rising to $360.2 million. In a separate disclosure, the CEO and two directors adopted 10b5-1 trading plans for future share sales—a routine but noteworthy governance update.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 29.9% of the 1661 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ANIP was trading at $75.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $64.99 to $99.50. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.